In the study of Sanders et al. on head and neck squamous cell carcinoma (HNSCC), Nectin-4 is expressed in approximately 86.2% of cases, with moderate to high expression in 32.7% and pronounced expression levels found in non-smokers and p16-positive patients, and its presence has been linked to improved overall survival, suggesting its potential as a prognostic biomarker and a therapeutic target [39]. This evidence concerns the gene NECTIN4 and head and neck squamous cell carcinoma.